| Useful Advices |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Business > Business > Five Questions to Ask When Writing a White Paper |
|
Useful Advices - Five Questions to Ask When Writing a White Paper
Writing white papers is not an easy task for most companies, but every company needs them to effectively educate and market their According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product products and services to potential customers. In many cases, white papers contain additional information and extra analyses, whic ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in aren’t included in other advertising or marketing materials. Your business can utilize white papers to reach a wider audience, b lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ut first you need to ask yourself these important questions: 1-Who is your audience? Make sure you analyze and define your here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe audience, so you can effectively convey your technical or business concepts to the reader. If needed, you can include an extra se d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro tion of your paper called “Intended Audience” in the body of your white paper. 2-Did you create an outline? It’s a good i ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc dea to structure your white paper accordingly, so that you present a solution to your business/industry problem. To use your time easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi wisely, I would recommend that you get your outline reviewed by experts of the subject before writing the entire paper. Make sure nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically to have supporting evidence to support your argument as well. Key components of a white paper should include the cover page, exec and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ tive summary, table of contents, body, summary & call to action, and lastly, the author’s biography or works cited page. It is im ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi ortant to make sure that your executive summary is clear and understandable, so that the reader can follow your in-depth descripti ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a on of your business problem in the following sections of your white paper. 3-Did you explain your diagrams or flow charts? dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod Many white papers include diagrams and flow charts. These require a thorough description and explanation. Make sure these diagr cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin ams are easy to follow and not too technical for the reader. 4-What kind of writing style are you using? White papers are tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen essentially marketing materials, but a little more meaty. Make sure the white paper is readable, but also beware of marketing-spe t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel k. White papers are typically more formal, but try to minimize technical jargon. Also, in developing the style of your white pape ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust r, you should also identify what type of white paper you’re writing. 5-What is the length? The shorter your paper, the bet y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products er. You want to make sure that the paper explains the complexity of your product or method, but it should never be longer than 15 . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de -pages. For more information on white paper guidelines: http://www.whitepapersource.com/writing/7steps.html http://www.klariti. elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip om/business-writing/more-guidelines-white-papers.shtml http://www.nwcg.gov/teams/pmo/products/documents/White_Paper_Guidelines.pd tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:How About Printing Your Own Business Cards? Traits of a Leader: First Lead Yourself Blackberry 8100 Pearl - The Smallest, Smartest Smartphone Yet
|